Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Capital Expenditures (2016 - 2025)

Dare Bioscience (DARE) has disclosed Capital Expenditures for 10 consecutive years, with -$151559.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 46.32% year-over-year to -$151559.0, compared with a TTM value of $741486.0 through Sep 2025, up 6329.93%, and an annual FY2024 reading of $573046.0, changed N/A over the prior year.
  • Capital Expenditures was -$151559.0 for Q3 2025 at Dare Bioscience, down from $172865.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $562849.0 in Q4 2024 and bottomed at -$282325.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $59234.0, with a median of $10910.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 2646.94% in 2024, while the deepest fall reached 1377.55% in 2024.
  • Year by year, Capital Expenditures stood at $14524.0 in 2021, then plummeted by 81.43% to $2697.0 in 2022, then crashed by 919.39% to -$22099.0 in 2023, then skyrocketed by 2646.94% to $562849.0 in 2024, then tumbled by 126.93% to -$151559.0 in 2025.
  • Business Quant data shows Capital Expenditures for DARE at -$151559.0 in Q3 2025, $172865.0 in Q2 2025, and $157331.0 in Q1 2025.